Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/43603
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRao V.-
dc.contributor.authorMunasinghe A.-
dc.date.accessioned2021-09-03T03:43:19Z-
dc.date.available2021-09-03T03:43:19Z-
dc.date.copyright2021-
dc.date.created20210512-
dc.date.issued2021-05-12en
dc.identifier.citationBMJ Case Reports. 14 (4) (no pagination), 2021. Article Number: e240719. Date of Publication: 28 Apr 2021.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/43603-
dc.description.abstractRivaroxaban is a commonly used anticoagulant agent for treatment and prevention of thromboembolism. There are case reports demonstrating an association between its use and drug-induced liver injury. However, this has not been reported in a patient who previously tolerated apixaban. An 88-year-old man presented to hospital with worsening lethargy, jaundice and vomiting. He had severely elevated liver transaminases, an abnormal coagulation profile and elevated bilirubin in keeping with acute liver injury. This is in the context of having had his anticoagulation medication switched from apixaban to rivaroxaban 2weeks prior. The patient recovered well after cessation of rivaroxaban, suggesting that it was the likely offending agent. The mechanism of rivaroxaban-induced liver injury remains to be investigated. Drug-induced liver injury should be discussed and monitored for as a potential adverse reaction when commencing rivaroxaban, even if a patient has previously tolerated a drug of the same class.Copyright © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.-
dc.publisherBMJ Publishing Group-
dc.relation.ispartofBMJ Case Reports-
dc.subject.meshactivated partial thromboplastin time-
dc.subject.meshacute liver failure/si [Side Effect]-
dc.subject.meshanemia/di [Diagnosis]-
dc.subject.mesharm weakness-
dc.subject.meshatrial fibrillation/dt [Drug Therapy]-
dc.subject.meshbilirubin blood level-
dc.subject.meshbody weight loss-
dc.subject.meshbone marrow biopsy-
dc.subject.meshbone marrow disease/di [Diagnosis]-
dc.subject.meshcarotid artery obstruction/di [Diagnosis]-
dc.subject.meshcolonoscopy-
dc.subject.meshcomputed tomographic angiography-
dc.subject.meshcomputer assisted tomography-
dc.subject.meshdisease exacerbation-
dc.subject.meshdisease severity-
dc.subject.meshdrug blood level-
dc.subject.meshdrug substitution-
dc.subject.meshdrug withdrawal-
dc.subject.meshechography-
dc.subject.mesherythrocyte-
dc.subject.meshesophagitis/di [Diagnosis]-
dc.subject.meshfatty liver/di [Diagnosis]-
dc.subject.meshgastritis/di [Diagnosis]-
dc.subject.meshgastroesophageal junction-
dc.subject.meshgastroscopy-
dc.subject.meshgene mutation-
dc.subject.meshhemoglobin blood level-
dc.subject.meshhyperbilirubinemia/di [Diagnosis]-
dc.subject.meshhypertransaminasemia-
dc.subject.meshinternational normalized ratio-
dc.subject.meshjaundice-
dc.subject.meshlaboratory test-
dc.subject.meshlength of stay-
dc.subject.meshlethargy-
dc.subject.meshlimb weakness-
dc.subject.meshlow drug dose-
dc.subject.meshmegakaryocyte-
dc.subject.meshmortality-
dc.subject.meshmyeloid metaplasia/di [Diagnosis]-
dc.subject.meshmyelophthisic anemia/di [Diagnosis]-
dc.subject.meshnausea-
dc.subject.meshoccult blood test-
dc.subject.meshrectum disease/di [Diagnosis]-
dc.subject.meshsplenomegaly/di [Diagnosis]-
dc.subject.meshthrombocytopenia/di [Diagnosis]-
dc.subject.meshtransient ischemic attack-
dc.subject.meshtreatment duration-
dc.subject.meshvery elderly-
dc.subject.meshvomiting-
dc.subject.meshacetylcysteine/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshaminotransferase/ec [Endogenous Compound]-
dc.subject.meshapixaban/ae [Adverse Drug Reaction]-
dc.subject.meshapixaban/dt [Drug Therapy]-
dc.subject.meshapixaban/po [Oral Drug Administration]-
dc.subject.meshapixaban/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshatorvastatin/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshbilirubin/ec [Endogenous Compound]-
dc.subject.meshenoxaparin/dt [Drug Therapy]-
dc.subject.meshenoxaparin/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshferritin/ec [Endogenous Compound]-
dc.subject.meshfresh frozen plasma/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshhemoglobin/ec [Endogenous Compound]-
dc.subject.meshJanus kinase 2/ec [Endogenous Compound]-
dc.subject.meshliver enzyme/ec [Endogenous Compound]-
dc.subject.meshrivaroxaban/ae [Adverse Drug Reaction]-
dc.subject.meshrivaroxaban/dt [Drug Therapy]-
dc.subject.meshrivaroxaban/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshverapamil/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshvitamin K group/pv [Special Situation for Pharmacovigilance]-
dc.subject.meshJAK2 gene-
dc.titleAcute liver failure after changing oral anticoagulant from apixaban to rivaroxaban.-
dc.typeArticle-
dc.identifier.affiliationNephrologyen
dc.identifier.affiliationGeneral Medicineen
dc.type.studyortrialCase series or case report-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1136/bcr-2020-240719-
dc.publisher.placeUnited Kingdom-
dc.identifier.pubmedid33910797 [http://www.ncbi.nlm.nih.gov/pubmed/?term=33910797]-
dc.identifier.institution(Rao) Department of General Medicine, Monash Medical Centre, Clayton, Melbourne, VIC, Australia-
dc.identifier.institution(Munasinghe) Department of Nephrology, Monash Medical Centre, Clayton, Melbourne, VIC, Australia-
dc.subect.keywordscase report-
dc.subect.keywordsfollow up-
dc.subect.keywordshuman-
dc.subect.keywordshuman tissue-
dc.subect.keywordsmale-
dc.subect.keywordsoutcome assessment-
dc.subect.keywordspriority journal-
dc.identifier.affiliationmh(Rao) Department of General Medicine, Monash Medical Centre, Clayton, Melbourne, VIC, Australia-
dc.identifier.affiliationmh(Munasinghe) Department of Nephrology, Monash Medical Centre, Clayton, Melbourne, VIC, Australia-
item.openairetypeArticle-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Appears in Collections:Articles
Show simple item record

Page view(s)

28
checked on May 1, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.